ESSA Pharma presented new preclinical data on ESSA’s lead Investigational New Drug candidate at the 2019 American Urological Association Annual Meeting. The studies demonstrate that, pre-clinically, EPI-7386: Displays similar in vitro IC50 potency compared to the ‘lutamide class of antiandrogens in an in vitro androgen receptor inhibition assay; Shows in vitro activity in several enzalutamide-resistant prostate cancer cell models in which enzalutamide is resistant; Exhibits a favorable metabolic profile across three preclinical animal species, which suggests that EPI-7386 will have high exposure and a long half-life in humans; Provides similar antitumor activity to enzalutamide in the enzalutamide-sensitive LNCaP prostate cancer xenograft model; Provides superior antitumor activity to enzalutamide, as a single agent or in combination with enzalutamide, in the enzalutamide-resistant VCaP prostate cancer xenograft model; AR inhibition with both an N-terminal domain inhibitor and a ligand binding domain inhibitor, induces deeper and more consistent anti-tumor responses in the enzalutamide-resistant VCaP xenograft model.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.